Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

International Journal of Obesity

Volumn 39, Issue 5, 2015, Pages 834-841

  Iepsen, E W ^a,b   Lundgren, J ^a,b   Dirksen, C ^b   Jensen, J Eb ^b   Pedersen, O ^a   Hansen, T ^a   Madsbad, S ^b   Holst, J J ^a   Torekov, S S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCOSE; INSULIN; LEPTIN; LEPTIN RECEPTOR; LIRAGLUTIDE; PEPTIDE YY [3-36]; TRIACYLGLYCEROL; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; AGONISTS; APPETITE; BLOOD; BODY MASS; CALORIC RESTRICTION; DENMARK; DIET THERAPY; DRUG EFFECTS; PREDIABETIC STATE; TREATMENT OUTCOME;

ADULT; APPETITE; BODY MASS INDEX; CALORIC RESTRICTION; DENMARK; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; LEPTIN; LIRAGLUTIDE; MALE; OBESITY; PREDIABETIC STATE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84928926835     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2014.177     Document Type: Article

References (48)

1. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31: S61-S78.
2. Wadden TA. Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Ann Intern Med 1993; 119: 688-693.
3. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
4. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond) 2010; 34: S47-S55.
5. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008; 118: 2583-2591.
6. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115: 3579-3586.
7. Kissileff HR, Thornton JC, Torres MI, Pavlovich K, Mayer LS, Kalari V et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr 2012; 95: 309-317.
8. Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowinski J. Free leptin index as a marker for leptin action in diabetes and obesity: leptin and soluble leptin receptors relationship with HbA1c. Neuro Endocrinol Lett 2010; 31: 679-683.
9. Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 2001; 283: 982-988.
10. Wu Z, Bidlingmaier M, Liu C, De Souza EB, Tschop M, Morrison KM et al. Quantification of the soluble leptin receptor in human blood by ligand-mediated immunofunctional assay. J Clin Endocrinol Metab 2002; 87: 2931-2939.
11. Kratzsch J, Lammert A, Bottner A, Seidel B, Mueller G, Thiery J et al. Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence. J Clin Endocrinol Metab 2002; 87: 4587-4594.
12. Schaab M, Kausch H, Klammt J, Nowicki M, Anderegg U, Gebhardt R et al. Novel regulatory mechanisms for generation of the soluble leptin receptor: implications for leptin action. PLoS One 2012; 7: e34787.
13. Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowinski J. Leptin, soluble leptin receptors, free leptin index, and their relationship with insulin resistance and BMI: high normal BMI is the threshold for serum leptin increase in humans. Horm Metab Res 2010; 42: 585-589.
14. Galgani JE, Greenway FL, Caglayan S, Wong ML, Licinio J, Ravussin E. Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients. J Clin Endocrinol Metab 2010; 95: 851-855.
15. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575.
16. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
17. Astrup A, Rossner S, Van GL, Rissanen A, Niskanen L, Al HM et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebocontrolled study. Lancet 2009; 374: 1606-1616.
18. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-dietinduced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37: 1443-1451.
19. Torekov SS, Holst JJ, Ehlers MR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 16: 451-456.
20. Torekov SS, Madsbad S, Holst JJ. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011; 12: 593-601.
21. Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity-GLP-1 and obesity. Expert Opin Pharmacother 2014; e-pub ahead of print 26 September 2014.
22. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006; 55: 3387-3393.
23. Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Kuchler D et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 2014; 63: 1422-1427.
24. Muller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, Grant E et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 2012; 18: 383-393.
25. Riecke BF, Christensen R, Christensen P, Leeds AR, Boesen M, Lohmander LS et al. Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial. Osteoarthritis Cartilage 2010; 18: 746-754.
26. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 1983; 24: 359-365.
27. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-539.
28. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011; 96: 2519-2524.
29. Allard C, Doyon M, Brown C, Carpentier AC, Langlois MF, Hivert MF. Lower leptin levels are associated with higher risk of weight gain over 2 years in healthy young adults. Appl Physiol Nutr Metab 2013; 38: 280-285.
30. Schaab M, Kausch H, Klammt J, Nowicki M, Anderegg U, Gebhardt R et al. Novel regulatory mechanisms for generation of the soluble leptin receptor: implications for leptin action. PLoS One 2012; 7: e34787.
31. Maamra M, Bidlingmaier M, Postel-Vinay MC, Wu Z, Strasburger CJ, Ross RJ. Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology 2001; 142: 4389-4393.
32. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53: 552-561.
33. Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 639-643.
34. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11.
35. Beavers DP, Beavers KM, Lyles MF, Nicklas BJ. Cardiometabolic risk after weight loss and subsequent weight regain in overweight and obese postmenopausal women. J Gerontol A Biol Sci Med Sci 2013; 68: 691-698.
36. Fonseca V, Madsbad S, Falahati, Zychma MJ, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic BP-A meta-analysis of 6 Clinical Trials. Diabetes 2009; 58: A146.
37. Torekov SS, Larsen LH, Glumer C, Borch-Johnsen K, Jorgensen T, Holst JJ et al. Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes. Diabetes 2005; 54: 2261-2265.
38. Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
39. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011; 13: 982-989.
40. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia 2013; 56: 1413-1416.
41. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277: R910-R916.
42. Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 1991; 129: 139-148.
43. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189-196.
44. Svendsen B, Pedersen J, Holst JJ. Glucagon-like peptide 1 secretion from proximal rat intestine. Diabetologia 2011; 54: S211-S211.
45. Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rossner S et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 689-697.
46. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes Obes Metab 2012; 14: 531-538.
47. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagonlike peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
48. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the oncedaily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793